Overview

A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Status:
COMPLETED
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
A study of the efficacy and safety of HRS-5965 capsules compared to eculizumab for 24 weeks in patients with PNH.
Phase:
PHASE3
Details
Lead Sponsor:
Chengdu Suncadia Medicine Co., Ltd.
Treatments:
eculizumab